Asset
TEBIPENEM PIVOXIL HYDROBROMIDE
Spero Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03395249 | phase1 | completed | 2017-10-20 | 2018-08-02 | Spero Therapeutics | Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 |
FDA applications (0)
This company has no applications containing this asset.